Search Research
Search across 105,000+ research abstracts, articles, substances, health topics, keywords, and actions.
Found 18 results for "Probiotics"
Articles (6)
View all
Oct 23, 2024
A Dozen Uses of Probiotics That Will Surprise You
probiotics are good for you. But here are twelve recently discovered benefits of probiotics that
Linda Woolven and Ted Snider
6 min
Apr 01, 2014
Probiotics: Essential Supplements or Waste of Money?
probiotic supplements on the shelves in natural food stores these days, you'd assume there
synchro.co
7 min
Oct 17, 2017
Prevent and Treat the Common Cold with Strain-Specific Probiotics
probiotics off the shelf, customize your selection this cold and flu season with evidence-based
AliLeVere
10 min
Aug 09, 2016
New Study Shows Probiotics May Prevent ADHD And Autism Spectrum Disorders
probiotics reduce the risk for brain disorders in children, including ADHD and autism spectrum disorders
doctormurray
6 min
Abstracts (6)
View allBifidobacterium animalis subsp. lactis BPL1® exhibits potential as a functional probiotic for relieving constipation.
Constipation is a common gastrointestinal (GI) state for which probiotics have shown promise as a relief. This study examined the laxative effects of the strainsubsp.CECT 8145 (BPL1) in a loperamide-induced rat model of constipation.Fifty-nine rats were divided into control and loperamide-induced constipation groups. Animals received a 3-day intervention with either placebo or probiotic BPL1at two doses: 1.5×10CFU (colony-forming units) (low) and 3×10CFU (high). The study assessed several parameters to determine the probiotic's effect, including: stool and gut characteristics, gastrointestinal transit time (GTT), gene expression and gut microbiome composition.: While loperamide significantly decreased stool number, weight and humidity, BPL1supplementation effectively restored these parameters, being more pronounced at a high dose. Microbiome analysis showed that BPL1at a low dose reduced the abundance ofand, associated with constipation. In addition,abundance was negatively correlated with stool humidity. Functional microbiome profiling indicated that BPL1suppressed pathways related to mucin degradation, vancomycin resistance and isoleucine biosynthesis while promoting L-lactate and pyridoxal-P (vitamin B6) biosynthesis, which may support gut motility and barrier integrity.subsp.BPL1exhibits potential as a functional probiotic for relieving constipation through improving stool excretion and consistency, inducing taxonomic changes and beneficial functional modulation of the intestinal microbiome. These findings justify further investigation into the mechanisms of BPL1as a probiotic for constipation management.
Andrea Rodenes-Gavidia, Anna Mas-Capdevilla, Adrián Florit, María Enrique López, Daniel González-Hedström, Araceli Lamelas, Patricia Martorell, Empar Chenoll, Vanessa Illescas-Armijo, Juan Martínez-Blanch, Anna Antolín, Juan María Alcaide-Hidalgo, Roger Mariné-Casadó, Antonia Rojas, Laura Rago, Nutrients
Animal Study
The role of Lactobacillus in dibutyl phthalate-induced gut and liver injury: Probiotic intervention and multi-omics evidence.
BACKGROUND: Dibutyl phthalate (DBP), a widespread environmental contaminant, induces hepatotoxicity. While the gut-liver axis is implicated, the specific role of gut microbiota, particularly key beneficial genera, remains obscure. OBJECTIVE: This study aimed to elucidate whether Lactobacillus depletion is a central event in DBP-induced gut-liver axis disruption and to evaluate the therapeutic potential of probiotic intervention. METHODS: Mice were exposed to DBP (0, 50, 100, 200 mg/kg/day) for 28 days. An intervention group received DBP (100 mg/kg/day) co-administered with Lactobacillus rhamnosus GG (LGG, 1 ×10CFU/day). Systemic toxicity was assessed via serum biochemistry and histopathology. Gut barrier integrity, oxidative stress, and inflammation were evaluated in the ileum and liver. Multi-omics analyses, including 16S rDNA sequencing of ileal microbiota, liver transcriptomics, and serum metabolomics, were integrated to uncover mechanistic links. RESULTS: DBP exposure induced dose-dependent hepatotoxicity (steatosis, elevated ALT/AST, oxidative stress, inflammation) and ileal injury (barrier disruption, dysbiosis). Crucially, DBP specifically and significantly depleted ileal Lactobacillus. Multi-omics integration revealed that Lactobacillus depletion was strongly correlated with disrupted sphingolipid metabolism, a pathway concurrently altered in the serum metabolome and liver transcriptome. Intervention with LGG significantly ameliorated both intestinal barrier dysfunction (restored tight junctions, reduced permeability) and hepatic injury (attenuated steatosis, oxidative stress, and inflammation). CONCLUSION: Our findings demonstrate that DBP-induced hepatotoxicity is mediated, in part, through the specific depletion of intestinal Lactobacillus, leading to gut barrier failure and systemic metabolic disturbances, notably in sphingolipid signaling. Probiotic supplementation with LGG effectively counteracts these defects. This study identifies Lactobacillus as a critical target of DBP and highlights microbiota-directed strategies as a promising avenue for mitigating phthalate toxicity.
Siming Huo, Bo Li, Jiayu Du, Zheng Cao, Ecotoxicol Environ Saf
Animal Study
Proteomic antibacterial characterization of flavonoid xanthohumol and probiotic Clostridium butyricum on pathogenic Clostridioides difficile.
BACKGROUND: The management of dysbiotic gut microbiota in Clostridioides difficile infection has attracted increasing scholarly attention. The development of therapeutic agents with low toxicity, derived from both the flavonoid xanthohumol and the short-chain fatty acid-producing probiotic Clostridium butyricum, holds considerable promise for combating Clostridioides difficile infection. Despite their therapeutic potential, the molecular mechanisms underlying the anti-Clostridioides difficile effects remain inadequately characterized. METHODS: In this study, we established a dextran sulfate sodium-induced inflammatory model using Caco-2 intestinal epithelial cells. The protective effects of xanthohumol against Clostridioides difficile infection superimposed on colitis were evaluated through cell viability assays, analysis of inflammatory signaling pathways, and proteomic profiling. Subsequent in vitro assays and proteomic analyses were conducted to assess the influence of xanthohumol and Clostridium butyricum supernatant on Clostridioides difficile. Furthermore, tandem mass tag-based post-translational modification proteomics was employed to elucidate the underlying molecular mechanisms and key pathways. Finally, critical metabolic enzyme activity assays were performed to validate the regulatory roles of these pathways. RESULTS: Xanthohumol significantly alleviated C. difficile-induced damage in Caco-2 cells, enhanced cell viability, and suppressed the activation of inflammatory signaling pathways. In vitro experiments demonstrated that both xanthohumol and C. butyricum supernatant reduced bacterial colonization, inhibited growth, and attenuated toxin production. Proteomic analyses revealed substantial alterations in the proteome of C. difficile in response to each treatment. Post-translational modification proteomics further indicated that both treatments modulate lysine acetylation levels, influencing glycolysis pathways and ultimately diminishing the pathogen's virulence. Furthermore, mass spectrometry identified a specific lysine acetylation at the K280 site of fructose-1,6-bisphosphate aldolase, a key enzyme in glycolysis. Functional validation via site-directed mutagenesis confirmed the essential role of this acetylation in regulating the catalytic activity of fructose-1,6-bisphosphate aldolase. CONCLUSIONS: Our study demonstrates that xanthohumol and Clostridium butyricum attenuate the pathogenicity of Clostridioides difficile through modulation of lysine acetylation and disruption of glycolysis metabolism. These findings highlight their potential as promising therapeutic strategies for treating Clostridioides difficile infection.
Shenkun Wei, Guorong Li, Qiong Yang, Xinping Zhu, Junjie Liang, Mengyi Liu, Zijian Chen, Xia Liu, Jun-Yu Xu, Wei Chen, Chin Med
Animal Study
Functionalized hydrogel sequentially deliver tannic acid and bioactive probiotics for radiation-induced skin injury.
As skin injuries caused by radiotherapy can significantly impede the healing process, it is essential to eliminate the interference of excessive reactive oxygen species (ROS) in the treatment of radiation-induced skin injury (RISI). To address this, we developed a temporally programmed hydrogel designed to enhance RISI repair, which was synthesized through the assembly of () and tannic acid (TA)-loaded hydrogel (Gel/LT). These hydrogels demonstrated satisfactory free radical scavenging capacity in the early stages, achieving an effective clearance rate of 93.3 %, thereby reducing the production of ROS associated with RISI. Furthermore, the encapsulated by metal-polyphenol self-assembly is released at the wound site in response to the wound microenvironment, promoting angiogenesis and tissue regeneration. Both and experiments demonstrated that Gel/LT achieved ROS scavenging and tissue repair effects at different stages of RISI. The transcriptome results indicate that these hydrogels facilitate a transition from an immune response to cellular proliferation by reducing oxidative stress and upregulating the expression of anti-inflammatory genes. Additionally, they promote the regeneration of extracellular matrix components, such as collagen, ultimately achieving superior repair efficacy compared to the commercial drug amifostine. This hierarchical therapeutic strategy permits temporal drug delivery at various stages of the repair process, presenting a novel approach for the treatment of RISI.
Han X, Zhou C, Xu R, Jia Z, Liu Y, Chen S, Tang W, Li X, Zhou L, Sun Y, Materials today. Bio
Combination of bacteriophage-probiotics alleviates intestinal barrier dysfunction by regulating gut microbiome in a chick model of multidrug-resistant Salmonella infection.
BACKGROUND: The rapid emergence of multidrug-resistant Salmonella in poultry demands alternative control strategies beyond conventional antibiotics. In this study, we evaluated a combination of lytic Salmonella-infecting bacteriophages (SLAM_phiST45 and SLAM_phiST56) and a probiotic bacterium Limosilactobacillus reuteri (SLAM_LAR11) in a chick model challenged with Salmonella enterica serovar Typhimurium infection. RESULTS: Co-administration with two-phage cocktail and a probiotic showed markedly reduced Salmonella colonization in the gut and systemic organs of chicks, comparable to the effect of phage-only treatment. In contrast with phage-only treatment, the combined therapy significantly improved the rate of body-weight change from the day of infection to necropsy (P < 0.0001) and alleviated infection-associated splenomegaly (P = 0.028) and hepatomegaly (P = 0.011). In the ileum, the villus height-to-crypt depth ratio (VH/CD) increased significantly (P = 0.044). In the colon, expression of tight-junction genes OCLN (P = 0.014), TJP1 (P < 0.0001), and MUC2 (P = 0.011) was elevated, whereas the pro-inflammatory cytokine IL6 was reduced (P = 0.018). These improvements were accompanied, in the cecum, by trends toward decreases in Escherichia-Shigella (P = 0.09) and Clostridium (P = 0.16) and a trend toward an increase in Blautia (P = 0.11); additionally, in the ileum, Lactobacillus (P = 0.037) and Blautia (P = 0.016) increased significantly, yielding a more balanced microbiota than with phage-only treatment. Consistently, levels of functional metabolites, including acetic acid (LDA = 3.32) and lactic acid (LDA = 5.29), were increased. CONCLUSION: Taken together, these findings demonstrate that phage-probiotic co-administration not only enhances the clearance of multidrug-resistant Salmonella more effectively than phage treatment alone but also promotes intestinal health, highlighting its potential as an antibiotic-alternatives strategy to improve intestinal health and ensure food safety in poultry production systems.
Choi Y, Kang A, Seo E, Lee DJ, Park J, Kim Y, Yu K, Yun CH, Jang KB, Kim WK, Shim K, Kang D, Kim Y, Journal of animal science and biotechnology
Videos (6)
View all
Video Feed
Mar 8, 2014
Do You Need Probiotics? Know the Basics
Would you benefit from taking probiotics? Dr. David Kiefer explains some of he basics about probiotics and who might benefit from taking them. He also explains the benefits to gut health as well as ov...
123 views
Video Feed
Feb 14, 2014
Dr. Mercola Talks About Complete Probiotics
Internationally renowned natural health physician and Mercola.com founder Dr. Joseph Mercola discusses new probiotics formula to get the best benefits.
79 views
Video Feed
Oct 21, 2016
Probiotics Reverse Problems Western Medicine Creates
The post Probiotics Reverse Problems Western Medicine Creates appeared first on GreenMedTV.
68 views
Video Feed
Sep 13, 2012
Dr. Mercola: Top 3 Recommended Supplements
Discover Dr. Mercola's top 3 supplements that will help you achieve optimal health: Krill Oil, Probiotics and Ubiquinol. These antioxidants will help maintain your great overall health and support you...
55 views
YouTube
Jun 23, 2016
Feeding Our Gut Bacteria Feeds Ourselves
The typical western diet is lacking in fiber, and it can cause our helpful bacteria to die off. This video was originally published on NutritionFacts.org and republished with permission. Nutrition...
49 views
